Organic Active Ingredients TRIZ Cases

Assessing phosphorylated tristetraprolin levels predicts treatment effectiveness while avoiding side effects from ineffective kinase inhibitor administration.

Oral imidazolyl ethanamide pentandioic acid combined with G-CSF treats radiation toxicity beyond the standard 24-hour window.

A process generates (S)-dihydroetorphine using a Diels-Alder reaction followed by hydrogenation and Grignard addition.

A 1,2-naphthoquinone derivative compound kills cancer cells effectively.

Novel pyrazolopyrimidinone compounds inhibit PDE1 enzymes to enhance neuronal signaling, addressing limited efficacy in neurodegenerative disorder treatments.

Niclosamide inhibits S100A4 transcription via Wnt pathway modulation.

A chiral catalyst mediates asymmetric synthesis of high-purity Sp-1 isomers.

Vortioxetine pyroglutamate forms an enteric gel that releases in the intestines, reducing gastrointestinal adverse events and improving bioavailability.

Amino acid salt complexes stabilize dihydromyricetin against degradation, improving solubility and efficacy while avoiding addiction risks.

Brush-arm star polymers encapsulate platinum agents in a hydrophobic core to reduce nephrotoxicity and neurotoxicity during cancer treatment.

Benzene-1,3,5-tricarboxamide derivatives form lipid-like nanoparticles to deliver mRNA efficiently despite limited understanding of LLN systems.

Substituted uracil derivatives inhibit chymase activity to reduce angiotensin II production and fibrosis, addressing the lack of effective enzyme inhibitors.

SC0062 pyrimidine sulfonamide derivative treats high altitude disease by resolving slow response and side effects through endothelin receptor antagonism.

Segmenting supplement doses into beadlets with varied dissolution rates prevents transporter saturation and reduces excretion.

KBU2046 targets Ser226 phosphorylation on HSP90β to inhibit cancer cell motility while minimizing cytotoxicity.

Homo- and heterodimeric Smac mimetic compounds disrupt Inhibitor of Apoptosis Protein interactions to induce apoptosis in cancer cells.

Mycelium export into liquid media retains the triple helix structure of beta glucans, solving absorption issues in dried powder treatments.

Handheld medical implant delivery device integrates an imaging lens to visualize tissue during surgical insertion.

Crystalline form N stabilizes aripiprazole production by eliminating hygroscopicity through isopropanol crystallization.

Comparing primary cilium structures between subject and normal specimens resolves the contradiction between diagnostic speed and objectivity.

Self-assembled gel compositions encapsulate therapeutic agents within nanostructures formed by enzyme-cleavable gelators.

Formula I ethynyl compounds target the mGluR4 allosteric site to improve symptom control while reducing adverse effects associated with dopaminergic therapies.

Palladium-catalyzed synthesis of TFM compounds inhibits CHK1 kinase to overcome cancer drug resistance.

Small molecule compounds disrupt EWS-FLI1 interactions with RHA helicase A, overcoming delivery and stability limits of antisense therapies.

A histidine cholesteryl ester carrier protects siRNA through self-assembly.

Formula I compounds inhibit alpha V beta 6 integrins, addressing limited oral deliverability of existing therapies.

Azaspirocyclic compounds inhibit monoacylglycerol lipase to modulate endocannabinoid signaling pathways.

Gene expression assays quantify multiple biomarkers in single biological samples to enable personalized cancer therapy selection.

Abidov adjuvant regulates macrophage activity and modulates cytokine production to boost specific immune responses in vaccine formulations.

Crosslinked collagen coatings deliver localized antibiotics without systemic toxicity, eliminating secondary surgeries.

Spiro-tetracyclic ring compounds modulate beta-secretase enzyme activity to reduce beta-amyloid peptide production.

Targeting ErbB2 rescues autophagic flux and clears APP-C99 without interfering with Notch signaling pathways.

Allosteric modulator compounds increase hemoglobin S oxygen affinity to treat sickle cell disease.

Novel fused pyrimidine compounds selectively inhibit class Ia PI3 kinases to treat hyperproliferative disorders.

Resveratrol 3-O-α-glucoside resolves the trade-off between composition stability and aqueous solubility by switching from β to α glycosidic bonds.

Indoprofen increases PGC-1α expression to convert muscle type II fibers, addressing metabolic decline in aging populations.

Pyrimidine compounds target P2X3 receptors to attenuate pain while minimizing taste disturbances caused by off-target effects.

LDN-193189 accelerates oligodendrocyte maturation by blocking BMP signaling, reducing culture time and boosting yield for demyelination therapies.

Aromatic excipients reduce viscosity and turbidity in high-concentration antisense oligonucleotide solutions, enabling effective therapeutic delivery.

Novel copolymers conjugated with protein antigens overcome hydrophobicity limits of TLR ligands, boosting dendritic cell maturation and immune response.

Cyclodextrin inclusion complexes mask blood smell and reduce gastrointestinal irritation while enhancing bioavailability.

A transdermal patch matrix uses tocopheryl phosphate and polymer carriers to enhance skin permeation of active compounds.

Immune regulatory oligonucleotides antagonize Toll-like receptors, potentiating TNF inhibitors to reduce infection and cancer risks in autoimmune treatment.

Cleavable linkers attach antibiotics to phages, enabling targeted biofilm disruption and effective treatment of resistant bacterial infections.

Protease-cleavable linkers release tubulysin payloads to boost tumor cell killing while minimizing systemic toxicity.

An arcuate intranasal delivery member deposits medication directly onto turbinate surfaces.